2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China) Successfully Concluded
2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China) Successfully Concluded
Innovation for the World, Exploring for the Future
为全球创新，开拓未来
SHENZHEN, China, July 1, 2024 /PRNewswire/ -- Recently, the "Innovation for the World, Exploring for the Future" 2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China), organized by Kexing Biopharm, was successfully concluded in Shanghai. Numerous industry experts, senior figures from the domestic pharmaceutical and investment sectors, as well as senior executives of pharmaceutical companies from around 20 countries and regions, such as Brazil, Russia, Singapore, South Korea, Malaysia, Saudi Arabia, and Africa, who closely collaborated with Kexing Biopharm attended this forum on sharing and effective discussions on the current status and development trends in the global medical market.
2024年7月1日，中国深圳——近日，由科兴制药组织的“为全球创新，开拓未来”2024国际制药合作高峰论坛科兴制药系列全球化活动（中国），在上海成功举办。来自巴西、俄罗斯、新加坡、韩国、马来西亚、沙特阿拉伯、非洲等约20个国家和地区的制药企业高管、国内制药和投资领域的高级人物以及众多行业专家，在与科兴制药密切合作的前提下，探讨了全球医疗市场的现状和发展趋势。
During the forum, Kexing Biopharm warmly welcomed and sincerely thanked the attendees from various backgrounds who had traveled from afar. In addition, they provided a comprehensive introduction to the Company's internationalization strategy and plans for the future. Kexing Biopharm emphasized its commitment to leveraging its overseas commercial platform to deliver high-quality products and comprehensive medication solutions for global patients. It specifically mentioned the successful acquisition of the EU GMP certificate for its first introduced product, albumin-bound paclitaxel, indicating a significant step forward in its global expansion. With a strong focus on international commercialization this year and leveraging years of international experience, the Company aims to become the best partner for high-quality Chinese pharmaceuticals worldwide.
在论坛期间，科兴制药热情欢迎并由衷感谢远道而来的各界嘉宾，全面介绍了公司的国际化战略及未来计划。科兴制药强调其致力于利用境外商业平台，为全球患者提供高品质产品和全面的药物解决方案。它明确提到了其首款推出的蛋白紧密结合的紫杉醇产品获得欧盟GMP认证的成功收购，标志着其全球扩张迈出了重要的一步。作为今年国际商业化重点和多年国际经验的积累，公司旨在成为全球优质中国药品的最佳合作伙伴。
Meanwhile, representatives from partner companies in Brazil, Malaysia, Saudi Arabia, and Africa, respectively shared insights into the local pharmaceutical development status, distribution channels, medication requirements, market access, and collaborative opportunities, providing clarification and showcasing the power of international win-win cooperation among the guests present at the event. Additionally, onsite strategic cooperation agreements were signed between Kexing Biopharm and various overseas partners, showcasing a reaffirmed commitment to continued collaboration and shared vision for the development of the pharmaceutical industry.
同时，来自巴西、马来西亚、沙特阿拉伯、非洲的合作伙伴代表分别分享了当地制药业发展现状、分销渠道、用药需求、市场准入和合作机会等观点，为在场嘉宾提供了解释并展示了国际共赢合作的强大力量。此外，科兴制药与多个海外合作伙伴签订了现场战略合作协议，展示了继续合作和共同发展制药行业的坚定承诺。
Simultaneously, during the CPHI exhibition from June 19th to 21, Kexing Biopharm presented a diverse portfolio of over twenty high-quality drugs covering the oncology pipeline, immunotherapy pipeline, metabolic disease pipeline, and nephropathy pipeline, including monoclonal antibodies, peptides, and small molecules.
同时，在6月19日至21日的CPHI展览期间，科兴制药展示了覆盖肿瘤药品管线、免疫治疗药品管线、代谢性疾病药品管线、肾病药品管线等领域的20多种高品质药品组合，包括单克隆抗体、肽类和小分子化合物。
News of victory keeps pouring in, on June 25, Kexing Biopharm (688136.SH) made it to the "2023 China Biopharmaceutical (Blood Product, Vaccine, and Insulin) Enterprise Top 20 List" in the "2023 China Pharmaceutical Industry Top 100 List Series," which was the third time in a row.
不断传来胜讯，2023年6月25日，科兴制药（688136.SH）连续第三年入选“2023中国生物制药（血制品、疫苗、胰岛素）企业前20强榜单”、“2023中国医药工业百强榜系列”的排名。